Latest news with #PTX
The Australian
2 days ago
- Business
- The Australian
Prescient advances cancer drug to unlock value
Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b trial to open commercial opportunities Special Report: Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market. Prescient Therapeutics (ASX:PTX) is in phase 2a trial for its lead compound PTX-100 in patients with rare blood cancer relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL) with the potential for its phase 2b arm to be registrational. PTX-100 is a first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1). It is believed to be the only GGT-1 inhibitor in the world in clinical development. The US Food and Drug Administration (FDA) has granted PTX-100 orphan drug designation (ODD) for all T-cell lymphomas and fast-track designation for treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL. Fast Track designation provides an expedited pathway to approval, with orphan drug designation offering market exclusivity for a period of seven years in the US. 'The aim is to improve the quality of life for people suffering from this terrible form of cancer and getting them the therapy they need as fast as possible,' CEO James McDonnell said. 'It's also an incentive for larger pharmaceuticals who are looking to add to their portfolio as the drug progresses through clinical development.' Potential regulatory trial for PTX-100 McDonnell is focused on getting PTX-100 through the phase 2a trial with the potential to make the second phase 2b arm a registration study. 'Fast Track designation opens a dialogue with the FDA for companies to provide ongoing trial updates, instead of a lengthy review at the end, to expedite therapies to patients who desperately need them,' he said. 'All we need to do is replicate the Phase 1b results, if the FDA agrees, they could potentially authorise Phase 2b as a registration study.' In the phase 1b trial PTX-100 delivered a 45% overall response rate and 64% clinical benefit in T-cell lymphoma, with just 4% serious side effects – well below the 30% benchmark. 'The first step now is to progress Phase 2a where we can define a dose which will also have some efficacy and safety data,' McDonnell said 'The registrational study means we are closer to approval and the momentum for PTX-100 really starts to accelerate and excitement grows on the commercial front.' Watch: James McDonnell discusses the first US site for the Phase 2a trial of PTX-100. Eyes on the commercialisation prize With over 27,000 new TCL cases every year, in eight major centres, PTX is targeting a market worth ~US$1.8 billion. Commercialisation of PTX-100 will become a key focus for Prescient if it advances to a registrational study, with all options on the table – including partnership, licensing, or taking the drug to market independently. 'We are confident in how PTX-100 could change the lives of thousands, we need the data now to back that confidence and provide the market a clear indication of the value the therapy can provide,' he said. 'PTX-100 is a first-in-class therapy with a unique mechanism of action which has shown very good results in the Phase 1b study. 'These results have exceeded our benchmarks and compare well to the available therapies on efficacy, duration and a safety perspective.' McDonnell said that Dimerix (ASX:DXB) was a great example of what a potential commercial pathway could look like for Prescient if Phase 2b became a registrational trial. Dimerix is advancing its lead candidate DMX-200 through the ACTION3 phase 3 trial for the rare kidney disease FSGS and has secured four regional licensing agreements to drive commercialisation. 'They were able to take orphan drug designated therapy DMX-200, which is currently in a phase 3 registration study, into significant licensing agreements worth approximately $1.4 billion,' he said. 'Dimerix have highlighted how these milestones, FDA designation and registrational study, can open commercialisation opportunities and drive value creation.' McDonnell said in biotech it often comes down to two questions with the first being: can you get a product to market? The second is: what kind of market is waiting at the end? Phase 2 trials usually provide clearer insights into a drug's potential, with data readouts serving as critical indicators that can drive value inflection points. Source: Prescient Therapeutics A series of upcoming catalyst Investors have plenty to watch out for in H2 CY25, with Prescient advancing its phase 2a study. 'We are excited for the release, once we reach 20 patients, of the initial data from the dose optimisation committee review, which will be a key event in determining the next steps for development of PTX-100,' McDonnell said. A share purchase plan aimed at raising $7 million to support Prescient's clinical program closed on July 25. 'There are several milestones we are looking to hit in the coming months and if we can potentially get that Phase 2b into a registration study we can start to shift our focus toward commercialisation opportunities,' McDonnell said. This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
News.com.au
08-07-2025
- Health
- News.com.au
WTF with PTX: Changing the game for T-Cell Lymphoma
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What therapies currently exist? And what changes can the healthcare sector make in this area? Tylah Tully is joined in this episode by Prescient Therapeutics (ASX:PTX) CEO James McDonnell to answer these questions and more. This video was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing. This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as WTF with PTX: Changing the game for T-Cell Lymphoma
Cision Canada
25-06-2025
- Business
- Cision Canada
Quincy Data's Precision Time Exchange Service Recognized as Best Time Stamping Measurement System by TradingTech Insight Awards
CHICAGO, June 25, 2025 /CNW/ -- Quincy Data, a global leader in high-performance financial market data distribution, has been named winner of the TradingTech Insight USA Award for Best Time Stamping Measurement System for its Precision Time Exchange (PTX) service. PTX delivers resilient, sub-nanosecond time synchronization across major North American trading venues, fully traceable to UTC(NIST). It offers a robust alternative to locally maintained GPS clocks, helping market participants address rising risks of interference and degradation in time signal reliability. According to Mike Schonberg, Director of Market Data Technology, "Timestamping that is reliable, picosecond-precise, and accurately available across multiple venues is an exceptionally hard technical challenge. PTX solves it. It is a uniquely resilient service that can replace the in-house time transfer systems financial firms are currently forced to build, maintain, and improve themselves." As uncertainty grows around the reliability of localized GPS infrastructure, time-sensitive institutions—including exchanges, ATSs, market makers, and data providers—are increasingly seeking dependable external time sources. PTX was engineered to support every major U.S. trading campus, enabling firms to avoid the burden of developing and managing their own precision timing systems. Firms prioritizing resiliency rely on PTX. Firms requiring precision rely on PTX. Firms demanding traceability rely on PTX. To explore how PTX can support your firm's timing needs, contact Quincy Data today. About Quincy Data Quincy Data is a global leader in the distribution of high-performance financial market data. The company delivers real-time market information tailored for every level of speed, richness, and precision. All services are provided on a level playing field to all clients.
Yahoo
25-06-2025
- Business
- Yahoo
Quincy Data's Precision Time Exchange Service Recognized as Best Time Stamping Measurement System by TradingTech Insight Awards
CHICAGO, June 25, 2025 /PRNewswire/ -- Quincy Data, a global leader in high-performance financial market data distribution, has been named winner of the TradingTech Insight USA Award for Best Time Stamping Measurement System for its Precision Time Exchange (PTX) service. PTX delivers resilient, sub-nanosecond time synchronization across major North American trading venues, fully traceable to UTC(NIST). It offers a robust alternative to locally maintained GPS clocks, helping market participants address rising risks of interference and degradation in time signal reliability. According to Mike Schonberg, Director of Market Data Technology, "Timestamping that is reliable, picosecond-precise, and accurately available across multiple venues is an exceptionally hard technical challenge. PTX solves it. It is a uniquely resilient service that can replace the in-house time transfer systems financial firms are currently forced to build, maintain, and improve themselves." As uncertainty grows around the reliability of localized GPS infrastructure, time-sensitive institutions—including exchanges, ATSs, market makers, and data providers—are increasingly seeking dependable external time sources. PTX was engineered to support every major U.S. trading campus, enabling firms to avoid the burden of developing and managing their own precision timing systems. Firms prioritizing resiliency rely on PTX. Firms requiring precision rely on PTX. Firms demanding traceability rely on PTX. To explore how PTX can support your firm's timing needs, contact Quincy Data today. About Quincy DataQuincy Data is a global leader in the distribution of high-performance financial market data. The company delivers real-time market information tailored for every level of speed, richness, and precision. All services are provided on a level playing field to all clients. View original content: SOURCE Quincy Data, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
PTX Metals Inc. Reports Further Highly Encouraging Drilling Results at Its W2 Cu-Ni-PGE and Gold Project
Toronto, Ontario--(Newsfile Corp. - June 3, 2025) - PTX Metals Inc. (TSXV: PTX) (OTCQB: PANXF) (FSE: 9PX) ("PTX" or the "Company"), a mineral exploration company focused on Cu-Ni-Au-PGE and Gold projects in Ontario, is pleased to release the following assay results from its Phase 1 of 2025 drilling program at the W2 Cu-Ni-PGE and Gold Project located in the Ring of Fire, northwestern Ontario, Canada (the "W2 Project"). Subsequently to the previous press release of May 27th, 2025, drill holes W225-08 and W225-12 are now being reported. Drilling has confirmed the presence of high-grade copper in multiple intervals above 1% Cu and consistent copper and nickel mineralization over broad widths in both drill holes W225-08 and W225-12. Additionally, drillhole W225-12 located in the CA2 zone of the Central Target, notably intercepted higher-grade palladium and platinum mineralization. This drill program has shown an improvement of both widths and grades from historical holes. Results from PTX's drilling include intersecting wide intercepts of encouraging grades near surface that continue to validate the potential of the exploration target issued last September, supporting a potential large bulk tonnage project. The results demonstrate a larger-scale system (~8 km in strike length) that encompasses the CA zones and the AP zones and a current goal to build a continuous system between CA1 and CA2 zones (see 3D geological model interpretation released on May 7th). Highlights - Drill Holes W225-08 and W225-12: Drillhole W225-08 intercepted a core length of 97.05m in the CA1 zone of near surface mineralization starting at 26.95m directly after the overburden. Drill hole W225-12, located in the CA2 zone 2.92 km to the East of CA1 zone, intersected 88.00m of sulphide mineralization demonstrating consistency of the mineralized body within the different identified zones. The highest grades by individual commodity in the two holes combined include: 1.80% copper, 0.74% nickel, 0.52 g/t gold, 1.05 g/t palladium and 0.55 g/t platinum and Cobalt 0.15% Drillhole W225-08 Drillhole W225-12 Table 1: Selected Results from drill holes W225-08 and W225-12. Intervals reported as core lengths. True widths are unknown at this time. To view an enhanced version of this graphic, please visit: Historical drilling was selective in assaying for all commodities and selective sampling procedures occurred. As a result, the Company has systematically assayed for Copper, Nickel, Gold, Palladium, Platinum and Cobalt and is now not reporting using Metal Equivalents and seen substantial improvements in the widths of mineralization with these practices. Additionally, for simplification purposes, Cu+Ni (%) and Au+Pt+Pd (g/t) are reported below as the arithmetic sum of individual commodity per interval chosen. Individual grades by commodity are also shown in table 1. Drill hole Analysis and Images: Drillhole W225-08, drilled into the CA1 Zone, was designed to infill and as a step out of hole 54004-0 drilled by Inco to the south, which reported some of the highest copper grade on the property [1] and a wide interval of consistent Nickel grade. The target was successfully intercepted starting from surface below the overburden at 26.95m depth and with 97.05m of mineralization within the main interval. Drilling has confirmed the presence of high-grade copper in multiple intervals above 1% Cu with up to 1.80% Cu and Nickel ranging between 0.20% and 0.70% within the mineralized interval as reported in Table 1 and in Figure 2. Drillhole W225-12 was designed to infill and as a step out of 130m to the east of W225-11 previously reported on May 27th, 2025. Both of PTX's holes showed not only higher-grade intervals but also a significant amount of palladium and platinum, where high-grade of 1.05g/t Pd was assayed in hole W225-12. Overall, the polymetallic system including copper, nickel, gold, platinum, palladium and cobalt occurs within consistent and similar wide intervals as shown in Figure 3. Figure 1: Plan Map showing CA1 and CA2 Zones along with drill hole locations for W225-08 and W225-12. Drillhole collars information is detailed in Table 2. Background is the reduced-to-pole total magnetic intensity (RTPTMI) derivative from the most recent Heli-GT 2025 magnetic survey. To view an enhanced version of this graphic, please visit: Figure 2: Cross section of drill hole W225-08, confirming historical drilling results in the CA1 zone previously intercepted in historical drill hole 54004-0. Refer to [1] below for historical drillholes data. To view an enhanced version of this graphic, please visit: Figure 3: Comparison side by side of grade of (Cu+Ni) and (Au+Pd+Pt) for drill hole W225-12. PGEs mineralization extends over 157m depth. To view an enhanced version of this graphic, please visit: High-grade individual commodity intersections within drill Hole W225-08 include: 1.53% Copper over 1.10 m from 50.85 m to 51.95 m 0.69% Nickel over 1.00 m from 43.00 m to 44.00 m 0.32 g/t Gold over 1.00 m from 114.00 m to 115.00 m 0.15 g/t Platinum over 0.57 m from 116.82 m to 116.82 m 0.41 g/t Palladium over 0.50 m from 137.94 m to 138.44 m 0.15 % Cobalt over 0.50 m from 64.50 m to 65.00 m High-grade individual commodity intersections within drill Hole W225-12 include: 1.80% Copper over 0.55 m from 105.61 m to 106.16 m 0.71% Nickel over 0.72 m from 99.33 m to 100.05 m 0.52 g/t Gold over 1.00 m from 56.00 m to 57.00 m 1.05 g/t Palladium over 1.00 m from 70.00 m to 71.00 m 0.55 g/t Platinum over 0.57 m from 102.91 m to 103.48 m 0.09 % Cobalt over 0.75 m from 102.16 m to 102.91 m Table 2: Drill Hole Collar Information Datum used in UTM NAD83 Z16N. DRILL OLE Easting Northing Elev (m) Azimuth Dip Length (m) W225-08 459,696 5,813,155 246 180 -55 146.00 W225-12 462,556 5,812,549 242 225 -55 159.00 [1] Data from historical drillhole were referred from a NI 43-101 report titled "NI 43-101 Updated Technical Report on the W2 Copper-Nickel-PGE Property" authored by I.A. Osmani et al., effective on September 4th, 2024. QAQC: Samples (NQ core diameter = 4.76 cm) were cut using a diamond blade saw, inserted into labeled bags, and delivered by representatives of PTX to Activation Laboratories Ltd. in Thunder Bay, Ontario. Activation Laboratories Ltd. is an ISO 17025:2005 accredited testing laboratory. Samples were analyzed for Au, Pt, and Pd using the lead fire-assay 1C-OES package, and multi-element analysis was completed by near-total digestion (four-acid) with an ICP-OES finish (1F2 package). For over-range samples (Cu, Ni) over 1% Cu or Nickel, the 8-4 Acid Near Total ICP-OES method was utilized. PTX inserted standards and blanks and performs duplicate analysis as part of its QA/QC program. Activation Laboratories also performs an internal QA/QC program which includes the insertion of CRM's, blanks, sample repeats, and duplicate samples. Qualified Person: The technical information presented in this news release has been reviewed and approved by Joerg Kleinboeck, P. Geo., a non-independent qualified person to PTX Metals who is responsible for ensuring that the related technical information provided in this news release is accurate and who act as a "qualified person" (QP) as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects. About PTX Metals Inc.: PTX is a mineral exploration company focused on high-quality strategic metals assets in northern Ontario, allowing exposure for shareholders to Copper, Gold, Nickel, and PGEs discovery. The Province of Ontario is renowned as a first-class mining jurisdiction for its abundance of mineral resources and safe jurisdiction. Our corporate objective is to advance our assets, and unveil the potential of two Flagship Projects, the W2 Cu-Ni-PGE located in the strategic Ring of Fire region, and the Shining Tree Gold Project neighbor to multi-million ounces gold deposits in the Timmins Gold Camp. PTX's portfolio of assets was strategically acquired for their geologically favorable attributes, and proximity to established mining companies. PTX is based in Toronto, Canada, with a primary listing on the TSX under the symbol PTX. The Company is also listed in Frankfurt under the symbol 9PF and on the OTCQB in the United States as PANXF. For additional information on PTX, please visit the Company's website at For further information, please contact: Greg Ferron, President and Chief Executive Officer Phone: +1 (416) 270-5042 Email: gferron@ Forward-Looking Information: This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information is characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, and opportunities to differ materially from those expressed or implied by such forward-looking information, including statements regarding the ability of the Company to satisfy the regulatory, stock exchange and commercial closing conditions of Private Placement, and the potential development of mineral resources and mineral reserves which may or may not occur. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and general economic and political conditions. Forward looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary approvals, including governmental and regulatory approvals, will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether because of new information, future events or otherwise, other than as required by applicable laws. For more information on the risks, uncertainties and assumptions that could cause our actual results to differ from current expectations, please refer to the Company's public filings available under the Company's profile at This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
